Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia
Zdenek Racil,
Filip Razga,
Jana Drapalova,
Lucie Buresova,
Daniela Zackova,
Martina Palackova,
Lukas Semerad,
Ludmila Malaskova,
Martin Haluzik,
Jiri Mayer
Affiliations
Zdenek Racil
Dept. Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic;CEITEC - Central European Institute of Technology, Masaryk University Brno, Brno, Czech Republic
Filip Razga
Dept. Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Jana Drapalova
3rd Dept. Medicine, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Lucie Buresova
Institute of Biostatistics and Analyses, Masaryk University Brno, Brno, Czech Republic
Daniela Zackova
Dept. Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Martina Palackova
Dept. Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Lukas Semerad
Dept. Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Ludmila Malaskova
Department of Clinical Biochemistry, University Hospital Brno, Brno, Czech Republic
Martin Haluzik
3rd Dept. Medicine, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Jiri Mayer
Dept. Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic;CEITEC - Central European Institute of Technology, Masaryk University Brno, Brno, Czech Republic
